PDS Biotechnology Corporation [NASDAQ: PDSB] closed the trading session at $5.66 on 04/07/21. The day’s price range saw the stock hit a low of $4.79, while the highest price level was $5.69. The company report on March 18, 2021 that PDS Biotech Reports Financial Results for the Year Ended December 31, 2020 and Provides Business Update.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced its financial results for the year ended December 31, 2020 and provided a business update.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Recent Business Highlights:.
The stocks have a year to date performance of 164.49 percent and weekly performance of 33.18 percent. The stock has been moved at 151.56 percent over the last six months. The stock has performed 52.56 percent around the most recent 30 days and changed 135.83 percent over the most recent 3-months.
If compared to the average trading volume of 1.66M shares, PDSB reached to a volume of 1168828 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about PDS Biotechnology Corporation [PDSB]:
H.C. Wainwright have made an estimate for PDS Biotechnology Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 10, 2020. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on May 27, 2020, representing the official price target for PDS Biotechnology Corporation stock. Previously, the target price had yet another raise to $5.45, while Noble Capital Markets analysts kept a Outperform rating on PDSB stock.
The Average True Range (ATR) for PDS Biotechnology Corporation is set at 0.55 The Price to Book ratio for the last quarter was 4.64, with the Price to Cash per share for the same quarter was set at 1.34.
PDSB stock trade performance evaluation
PDS Biotechnology Corporation [PDSB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.18. With this latest performance, PDSB shares gained by 52.56% in over the last four-week period, additionally plugging by 151.56% over the last 6 months – not to mention a rise of 686.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PDSB stock in for the last two-week period is set at 62.83, with the RSI for the last a single of trading hit 69.28, and the three-weeks RSI is set at 60.12 for PDS Biotechnology Corporation [PDSB]. The present Moving Average for the last 50 days of trading for this stock 4.53, while it was recorded at 4.92 for the last single week of trading, and 2.98 for the last 200 days.
PDS Biotechnology Corporation [PDSB]: An insightful look at the core fundamentals
Return on Total Capital for PDSB is now -75.57, given the latest momentum, and Return on Invested Capital for the company is -75.53. Return on Equity for this stock declined to -76.48, with Return on Assets sitting at -65.43. When it comes to the capital structure of this company, PDS Biotechnology Corporation [PDSB] has a Total Debt to Total Equity ratio set at 2.25. Additionally, PDSB Total Debt to Total Capital is recorded at 2.20, with Total Debt to Total Assets ending up at 1.98. Long-Term Debt to Equity for the company is recorded at 1.81, with the Long-Term Debt to Total Capital now at 1.77.
Reflecting on the efficiency of the workforce at the company, PDS Biotechnology Corporation [PDSB] managed to generate an average of -$989,825 per employee.PDS Biotechnology Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.30 and a Current Ratio set at 9.30.
Earnings per share (EPS) analysis for PDS Biotechnology Corporation [PDSB] stock
With the latest financial reports released by the company, PDS Biotechnology Corporation posted -0.39/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -160.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PDSB.
PDS Biotechnology Corporation [PDSB]: Insider Ownership positions
There are presently around $18 million, or 14.10% of PDSB stock, in the hands of institutional investors. The top three institutional holders of PDSB stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 828,721, which is approximately 5.723% of the company’s market cap and around 27.61% of the total institutional ownership; VANGUARD GROUP INC, holding 714,037 shares of the stock with an approximate value of $4.04 million in PDSB stocks shares; and FEDERATED HERMES, INC., currently with $2.17 million in PDSB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in PDS Biotechnology Corporation stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 15 institutional holders increased their position in PDS Biotechnology Corporation [NASDAQ:PDSB] by around 343,573 shares. Additionally, 9 investors decreased positions by around 493,305 shares, while 12 investors held positions by with 2,308,437 shares. The mentioned changes placed institutional holdings at 3,145,315 shares, according to the latest SEC report filing. PDSB stock had 7 new institutional investments in for a total of 114,932 shares, while 7 institutional investors sold positions of 472,250 shares during the same period.